Acadia’s Trofinetide Shows Efficacy In Rett Syndrome, But Safety Looks Shaky
Executive Summary
Trofinetide could be the first approved drug for Rett patients after hitting both co-primary endpoints in a Phase III trial, but high rates of diarrhea and vomiting raise questions.
You may also be interested in...
Keeping Track: Incyte’s Opzelura Earns First Vitiligo Claim; NDAs From Apellis, Acadia
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Anavex Reveals Positive Phase III Data In Rett Syndrome But A Surprise Endpoint
The endpoint used in the AVATAR trial was different than the one investors had expected; management said the change was made to satisfy the US FDA.
Newron STARS Fade With Sarizotan Failure
Sarizotan, licensed from Merck KGaA in 2011 for Rett syndrome, was seen as a potential gamechanger for Newron but the termination of the project leaves a huge hole in the Italian group's pipeline.